FDA grants priority review to Biologics License Application for idarucizumab

Biospace Inc.

Idarucizumab, a humanised antibody fragment, is being investigated to specifically reverse the anticoagulant effect of dabigatran in patients needing emergency intervention or experiencing an uncontrolled or life-threatening bleeding event.

Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban

Hospital Pharmacy

Retrospective claims analysis (n=134, rivaroxaban [RV], n=536 historical LMWH/warfarin-treated patients) found availability of RV reduced
hospitalisation rate in patients with DVT treated with RV vs. what it would have been if only LMWH/warfarin were available (60% vs. 82%).

Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis

National Institute for Health Research

No new trials were located; the review was therefore largely based on the evidence available for TA182 (TRITON-TIMI 38 trial). A new economic model confirmed prasugrel is likely to be a cost-effective treatment option when compared with clopidogrel for all subgroups considered.

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services